Wei Li

8303946, Nov 6, 2012

Sep 2, 2003

10/654273

Margo A. Brinton - Decatur GA, US
Wei Li - Wayland MA, US

Georgia State University Foundation, Inc. - Atlanta GA

C12N 15/00
C12N 15/33
C12N 15/86
C12Q 1/68
C12Q 1/70

424 931, 424 9321, 424 932, 435456, 435 5, 435 61

The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to inhibition of flavivirus replication wherein the replication is effected by changing the normal interactions of the host cell protein TIAR or TIA-1.

20070010008, Jan 11, 2007

Jun 28, 2006

11/476376

Scheffer Tseng - Pinecrest FL, US
Hua He - Miami FL, US
Wei Li - Miami FL, US

C12N 5/06
C12N 5/08

435325000, 435366000

An ex vivo method of expanding animal cells whose differentiation state is controllable by modulating TGF-β signaling includes the steps of: (a) providing an animal subject having cells with a first phenotype; (b) isolating the cells from the animal subject; (c) placing the cells in an ex vivo culture system including a culture vessel having at least one surface and a medium in contact with the at least one surface, the medium being essentially free of intact amniotic membrane and feeder cells; and (d) culturing the cells in the medium under conditions which downregulate TGF-β signaling in the cells and allow the cells to proliferate while maintaining the first phenotype.

20100166704, Jul 1, 2010

Apr 7, 2008

12/082095

Margo A. Brinton - Decatur GA, US
Mohamed M. Emara - Roswell GA, US
Wei Li - Wayland MA, US

A61K 38/21
A61K 39/395
A61K 35/76
A61K 38/00
A61K 38/16
A61K 31/7088

424 854, 4241301, 424 936, 514 2, 514 12, 514 44 R

The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to inhibition of flavivirus replication wherein the replication is affected by changing the normal interactions of the host cell protein TIAR or TIA-1.

20110207628, Aug 25, 2011

Jun 9, 2009

13/062860

Wei Li - Miami Beach FL, US
Xiaoyu Jiang - Miami FL, US
Nora Blanca Caberoy - Miami FL, US

UNIVERSITY OF MIAMI - Miami FL

C40B 30/04
C40B 40/08
C12Q 1/68
C12N 15/63

506 9, 506 17, 435 612, 4353201

A dual display phage system for the identification of protein interaction networks and therapeutic targets.

20120093761, Apr 19, 2012

Apr 1, 2010

13/262285

Pirouz M. Daftarian - Miami FL, US
Paolo Serafini - Miami Shores FL, US
Vance Paul Lemmon - Miami FL, US
Angel Kaifer - Coral Gables FL, US
Victor L. Perez - Pinecrest FL, US
Wei Li - Miami FL, US
Bonnie Beth Blomberg - Coral Gables FL, US

UNIVERSITY OF MIAMI - Miami FL

A61K 31/785
A61P 35/00
C12N 15/09
A61P 37/04
C08G 69/48
C12N 5/07

424 7817, 525 541, 435375, 435440

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle -based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.

20220202984, Jun 30, 2022

Mar 15, 2022

17/695112

- Norcross GA, US
Wei Li - Norcross GA, US
Yuan Di - Norcross GA, US
Annie You - Norcross GA, US
Low Wee Fong - Singapore, SG

A61L 9/22
A61L 9/20
A61L 2/10
A61L 2/24
A61L 2/26

A germicidal device includes a purification/disinfection and LED lighting member configured to generate UVC light and negative air ions for destroying microorganisms and removing odors in a space in which the purification and sterilization member is placed; a sensing member configured to detect at least one event occurred in said space in real time; and a microcontroller unit coupled with the purification and sterilization member and the sensing member for controlling operations of the purification and sterilization member in a respective state in accordance with the at least one event occurred in said space and energy saving. The UVC light has one or more wavelengths in a range of about 100-400 nm.

20200238065, Jul 30, 2020

Oct 11, 2018

16/755449

- Atlanta GA, US
Richard N. TERRY - Conyers GA, US
Wei LI - Atlanta GA, US

A61M 37/00
A61K 31/57
A61K 9/46
A61K 9/00

Separable microneedle arrays and microneedle patches are provided that may achieve sustained release of drug. The microneedle arrays may include one or more features that facilitate separation of the microneedles, such as a bubble structure. The microneedle arrays may include an effervescent material.

20190204302, Jul 4, 2019

Jan 2, 2018

15/860170

Wei Li - Miami FL, US

G01N 33/53
A61P 3/10
A61P 35/00
C12Q 1/02
G01N 33/15
C12Q 1/68
A61P 27/10
C12N 15/09
C07K 16/28

The present invention is directed to methods for systematic identification of cellular ligands, disease-associated ligands, age-related ligands and receptor-specific ligands. Disease-associated ligands are promising targets to develop novel ligand-based therapies. The methods are broadly applicable to any type of cells or diseases in in vitro and in vivo settings. This invention further used the methods to identify Scg3 as a disease-related angiogenic factor for the therapy of diabetic retinopathy, diabetic macular edema, proliferative diabetic retinopathy, vascular age-related macular degeneration, diabetic foot and cancers.